A. van Oosterom

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

Sigrid Stroobants, J. Goeminne, M. Seegers et al. · European Journal of Cancer · 2003 · 526 citations

Oncologic Imaging, Medical Imaging, Imatinib Mesylate +10

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 492 citations · Full text

Pkc412 Inhibitor, Imatinib-resistant Mutants, Gastrointestinal Oncology +9

Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

Grant A. McArthur, George D. Demetri, A. van Oosterom et al. · Journal of Clinical Oncology · 2005 · 477 citations

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

Axel Le Cesne, Jean‐Yves Blay, Ian Judson et al. · Journal of Clinical Oncology · 2005 · 418 citations

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

Jaap Verweij, A. van Oosterom, Jean‐Yves Blay et al. · European Journal of Cancer · 2003 · 402 citations

Oncology, Gastrointestinal Oncology, Molecular Target +10